ライフサイエンスコーパス: SCID mouse

1 nto skin allografts in vivo in the humanized SCID mouse.

2 emely sensitive model of MCMV infection, the SCID mouse.

3 y to reverse hyperglycemia in a diabetic NOD-scid mouse.

4 l heart tissues s.c. into the ear pinna of a SCID mouse.

5 n 18,000 to 1 in 1,851,000 cells) in the NOD/SCID mouse.

6 ion in vivo were studied in the diabetic NOD-SCID mouse.

7 ctivated PBL and in vivo using the human PBL-SCID mouse.

8 G(-/-) mouse can transfer diabetes to an NOD.scid mouse.

9 that is both more attenuated than BCG in the SCID mouse and more potent than BCG in the guinea pig.

10 MFD-1 was tumorigenic in SCID mouse and proliferative and invasive in 3D cultures

11 The genetically defective SCID mouse arose spontaneously from its parental strain

12 -Lin(-) cells were needed to engraft the NOD/SCID mouse as compared with the more permissive NOD/SCID

13 ue, Nakamura et al. (2013) describe a robust SCID mouse-based method for isolating human monoclonal a

14 cted in human precursor cells present in the SCID mouse BM and in leukocytes circulating in the perip

15 man CD14+ and CD19+ cells recovered from NOD/SCID mouse bone marrow and spleen following reconstituti

16 These results were confirmed in vivo in the scid mouse brain xenograft model in which propagation of

17 the C.B.17 severe combined immunodeficiency (scid) mouse brain.

18 ocytoma clones injected intracerebrally into SCID mouse brains promotes tumor cell proliferation.

19 -2 therapy can prevent EBV-LPD in the hu-PBL-SCID mouse, but protection is lost if murine natural kil

20 The findings indicate that the NOD/scid mouse can provide a unique tool for studying DITP p

21 lear cell (MNC) homing in vivo into an RA ST-SCID mouse chimera (P < 0.05).

22 We used an RA synovial tissue (ST)-SCID mouse chimera model to evaluate the role of H-2g in

23 study outline the effectiveness of the human-SCID mouse chimera system as a viable animal model of go

24 We utilized the RA synovial tissue SCID mouse chimera system to examine human microvascular

25 ed normal human ST was then examined in this SCID mouse chimera system.

26 Using a human RA ST-SCID mouse chimera, immunohistochemistry, enzyme-linked

27 H-2g-induced MNC recruitment into the RA ST-SCID mouse chimera.

28 doptive T cell transfer into temporal artery-SCID mouse chimeras demonstrated that DCs in healthy art

29 trating macrophages in human temporal artery-SCID mouse chimeras disrupted nitrotyrosine generation,

30 nes adoptively transferred into human tissue-SCID mouse chimeras infiltrated rheumatoid synovium but

31 Normal human ST-SCID mouse chimeras injected intragraft with gouty SF th

32 synovitis was confirmed by treating synovium-SCID mouse chimeras with IL-16.

33 RIL were explored by treating human synovium-SCID mouse chimeras with the APRIL and BLyS decoy recept

34 ansferred into rheumatoid arthritis synovium-SCID mouse chimeras, these CD4 T cell clones enhanced th

35 CD8 T cells were depleted in human synovium-SCID mouse chimeras.

36 ptive transfer experiments in human synovium-SCID mouse chimeras.

37 the atheroma was examined in human atheroma-SCID mouse chimeras.

38 human skin/severe combined immunodeficiency (SCID) mouse chimeras bearing tumors of MCF-7.

39 ral artery-severe combined immunodeficiency (SCID) mouse chimeras were created by engrafting inflamed

40 n synovium-severe combined immunodeficiency (SCID) mouse chimeras were treated with TSP2-transfected

41 ral artery-severe combined immunodeficiency (SCID) mouse chimeras with the AR inhibitors Sorbinil and

42 man artery-severe combined immunodeficiency (SCID) mouse chimeras, adoptively transferred human T cel

43 GCA artery-severe combined immunodeficiency (SCID) mouse chimeras, depletion of CD83(+) dendritic cel

44 r either myelin or nonmyelin Ag, entered the SCID mouse CNS within 3-5 days of cell transfer and caus

45 ies that lead to fatal EBV-LPD in the hu-PBL-SCID mouse depleted of murine NK cells, and they point t

46 posed of DC and macrophages obtained from B6 SCID mouse donors.

47 scid mouse embryonic fibroblasts are deficient in DNA-de

48 e used the severe combined immune deficient (SCID) mouse engrafted with human leukocytes (hu-PBL-SCID

49 mber of the severe combined immunodeficient (SCID) mouse eye and subsequently was inoculated with HCM

50 When transferred with recipient APC into a SCID mouse footpad, CD4(+) T cells were hyporesponsive i

51 veal melanoma growth in the same nude rat or SCID mouse for up to a month.

52 e diabetic/severe combined immunodeficiency (SCID) mouse has been a particularly useful model.

53 Cell lines derived from the SCID mouse have been utilised as a model DNA-PKcs-defect

54 using the severe combined immune deficiency (SCID) mouse HIV encephalitis model, which involves intra

55 exhibited less virulence than HSV-1 F in the SCID mouse host, enabling analysis of infection in human

56 (HSE, also called Apligraf) in the humanized SCID mouse (hu-PBL-SCID).

57 a chimeric severe combined immunodeficiency (SCID) mouse (hu-SCID) model, that human V gamma 2V delta

58 trophozoites and human intestine, we used a SCID mouse-human intestinal xenograft (SCID-HU-INT) mode

59 SCID mouse-human JRA synovium chimeras may provide a goo

60 m using the severe combined immunodeficient (SCID) mouse-human skin model of psoriasis.

61 In a chimeric SCID mouse/human synovial tissue (ST) model, mice were e

62 capable of preventing EBV-LPD in the hu-PBL-SCID mouse in the absence of murine NK cells.

63 l clone, BDC-6.9, in the immunodeficient NOD-scid mouse induces destruction of pancreatic beta-cells

64 on was required by B. burgdorferi throughout SCID mouse infection if the vlsE gene were absent.

65 l transfer severe combined immunodeficiency (SCID) mouse inflammatory bowel disease model demonstrate

66 An ICR/SCID mouse insulinoma model was used to show that insuli

67 e CB17 mice inhibited growth of T3C9 in CB17 SCID mouse intestine 11 days after p.o. inoculation.

68 Using a xenogeneic scid mouse intracranial glioma model, R4009 therapy of e

69 In a syngeneic scid mouse intracranial tumor model, recombinant herpes

70 oriatic human skin on transplantation to the SCID mouse is mediated, in large part, by amphiregulin.

71 he normal severe combined immune deficiency (SCID) mouse life span, although they contain proliferati

72 iabetic/severe combined immunodeficient (NOD/SCID) mouse line harboring a complete null mutation of t

73 In the humanized SCID mouse, local injection of Netrin-1 into skin enhanc

74 nts leading to efficacy in the P. falciparum SCID mouse malaria model.

75 recently developed non-obese diabetic (NOD)/SCID mouse may expand the uses of the SCID model.

76 We used three complementary strategies in a SCID mouse model and also addressed the underlying molec

77 y stronger antitumor activity in a xenograft SCID mouse model and depletes B cells in cynomolgus monk

78 a human disseminated CD23(+) B-cell lymphoma SCID mouse model and found greater antitumor activity wi

79 double auxotroph is fully attenuated in the SCID mouse model and highly immunogenic and protective i

80 yellow fever virus neuropathogenesis in the SCID mouse model and that the neuroinvasive properties d

81 hybrid fusion protein was as effective in a SCID mouse model as a fully active Ab-IL-2 fusion protei

82 We developed and validated a human (hu)RBC-SCID mouse model by giving nonobese diabetic/SCID mice d

83 ogether, these results validate the hHGF(tg)-SCID mouse model for in vivo determination of MET sensit

84 A JAK3 -/- SCID mouse model for the human disease has been used to

85 airs VZV infection of skin xenografts in the SCID mouse model in vivo.

86 wth factor 1 when transplanted into the same SCID mouse model of acute myocardial infarction where th

87 ession is required for full virulence in the SCID mouse model of amebic liver abscess, but E. histoly

88 nd improves overall survival in the Emu-TCL1-SCID mouse model of CLL with minimal weight loss or othe

89 Here we use the hu-PBL-SCID mouse model of Epstein-Barr virus (EBV)-associated

90 Second, a SCID mouse model of HIV-1 encephalitis (HIVE) was used t

91 data, taken together, demonstrate that this SCID mouse model of HIV-1 neuropathogenesis can reproduc

92 c CTL responses in a nonobese diabetic (NOD)-SCID mouse model of HIVE.

93 Comparable results were obtained with a SCID mouse model of human melanoma.

94 In a SCID mouse model of human NSCLC tumorigenesis, expressio

95 Using an SCID mouse model of human prostate cancer metastasis, we

96 c factors in JRA synovium, and to evaluate a SCID mouse model of JRA as an approach to study in vivo

97 The high in vivo efficacy in a SCID mouse model of P. falciparum malaria, good oral bio

98 tivity (IC50 = 10 nM) and oral activity in a SCID mouse model of Pf infection with an ED50 of 100 and

99 Using a SCID mouse model of Pneumocystis carinii pneumonia, we w

100 F invasion into coimplanted cartilage in the SCID mouse model of RA.

101 ZV infection of human skin xenografts in the SCID mouse model of VZV pathogenesis showed both that pC

102 seen after inoculation of human skin in the SCID mouse model or monolayers with higher-titered infec

103 granulation of human mast cells in the human/SCID mouse model provokes cellular inflammation in skin.

104 The Hu-PBL-SCID mouse model system, when used with appropriate phyl

105 a P. falciparum infection in a humanized NOD/SCID mouse model system.

106 urther demonstrate the utility of the huPBMC-SCID mouse model to investigate the molecular and cellul

107 livery system, was used in an insulinoma ICR/SCID mouse model to prevent hypoglycemic death.

108 ssessed against P. falciparum in the in vivo SCID mouse model where the efficacy was found to be more

109 e erythrocytic stage of P. falciparum in the SCID mouse model with an ED90 of 11.7 mg/kg when dosed o

110 om all of the groups produced disease in the SCID mouse model, and genogroup-consistent trends were n

111 al infarct (MI) in the immunocompromised NOD-SCID mouse model, and monitored the effects of myocardia

112 Moreover, in a humanized SCID mouse model, CD19(+) CD5(-) B cells were more effec

113 In the reconstituted SCID mouse model, depletion of CD8+ cells in addition to

114 ve against primary T. cruzi infection in our SCID mouse model, protective secondary effector function

115 s show the usefulness of the newly developed SCID mouse model, SN7-dgRA, and the clonotype-specific P

116 ng both in vitro systems and a humanized NOD/SCID mouse model, we demonstrate that BRCA1 expression i

117 Using a humanized SCID mouse model, we demonstrate that soluble and membra

118 a undetectable in vivo using a P. falciparum SCID mouse model.

119 ated cartilage invasion were examined in the SCID mouse model.

120 determinants of viral neuroinvasiveness in a SCID mouse model.

121 h that of neonatal skin grafts in the huPBMC-SCID mouse model.

122 an MM cell growth and prolongs survival in a SCID mouse model.

123 e resolution of primary RV infection using a SCID mouse model.

124 PC-3 tumor growth in a human prostate cancer/SCID mouse model.

125 nts in the human peripheral blood lymphocyte-SCID mouse model.

126 isolates of HIV-1 in vivo, using the hu-PBL-SCID mouse model.

127 of human and nonhuman primate T cells in the SCID mouse model.

128 ls metastasized to axillary lymph nodes in a SCID mouse model.

129 ne in the recently established P. falciparum SCID mouse model.

130 and IgE plasma cell numbers in a human PBMC-SCID mouse model.

131 uated for their roles in this phenotype in a SCID mouse model.

132 determinant of YFV neuroinvasiveness in the SCID mouse model.

133 a severe combined immunodeficiency disease (SCID) mouse model and enhanced antitumor activity.

134 A new severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated huma

135 a severe combined immunodeficiency disease (SCID) mouse model in vivo.

136 mononuclear cell reconstituted SCID (huPBMC-SCID) mouse model of allograft rejection, we compared th

137 we used the severe combined immunodeficient (SCID) mouse model of amebic liver abscess formation and

138 ocytes in a severe combined immunodeficient (SCID) mouse model of amebic liver abscess.

139 xenograft severe combined immunodeficiency (SCID) mouse model of disseminated B-cell lymphoma/leukem

140 In a severe combined immunodeficient (SCID) mouse model of disseminated, residual lymphoma, an

141 nction in a severe combined immunodeficient (SCID) mouse model of HIV-1 encephalitis (HIVE).

142 Using a severe combined immunodeficient (SCID) mouse model of HIVE, we determined the effects of

143 sted with a severe combined immunodeficient (SCID) mouse model of human prostatic cancer and an immun

144 compromized severe combined immunodeficient (SCID) mouse model of orthotopic breast cancer.

145 fts in the severe combined immunodeficiency (SCID) mouse model of VZV pathogenesis, and observed that

146 combined immunodeficiency (beta(2)m(-/-) NOD/SCID) mouse model paralleled clinical observations in hu

147 he severe combined immunodeficiency disease (SCID) mouse model, culture-expanded, cryopreserved human

148 Using a severe combined immunodeficient (SCID) mouse model, we demonstrate that enhanced expressi

149 formed in a severe combined immunodeficient (SCID) mouse model.

150 r xenograft/severe combined immunodeficient (SCID) mouse model.

151 g a human/severe combined immune deficiency (SCID) mouse model.

152 onses in a severe combined immunodeficiency (SCID) mouse model.

153 tumors in severe combined immunodeficiency (SCID) mouse model.

154 orthotopic severe combined immunodeficient (SCID) mouse model.

155 Both the Tax-transgenic and engrafted SCID mouse models allow for the analysis of cellular eve

156 Five frequently used SCID mouse models and their specific applications are su

157 .5 in murine melanoma-C57 and human melanoma-Scid mouse models, respectively.

158 s derived from HCT-116 and NCI-H460 cells in SCID mouse models.

159 phoma and Hodgkin lymphoma cells and in vivo SCID mouse models.

160 s, we investigated whether shaving occurs in SCID mouse models.

161 ib was confirmed using 2 different xenograft SCID mouse models: human MM injected subcutaneously (the

162 dium berghei malaria model as well as in the SCID mouse P. falciparum model.

163 th mouse passage but could be resurrected by SCID mouse passage.

164 iabetic/severe combined immunodeficient (NOD/SCID) mouse prostate or s.c., the alpha2beta1(+/hi) pros

165 The data suggest that the HSV-infected SCID mouse provides a proinflammatory microenvironment t

166 The hu-SRC-SCID mouse provides an unprecedented opportunity to gain

167 The severe combined immunodeficient (SCID) mouse provides such a model.

168 , using the severe combined immunodeficient (SCID) mouse-psoriasis xenograft model, we report therape

169 ecause serum levels of CCL5 were the same in SCID mouse recipients receiving cells from either WT or

170 lls, because the arthritis that developed in SCID mouse recipients was similar to that in WT and CCR5

171 der the kidney capsule of 3Gy irradiated NOD/SCID mouse recipients.

172 g stem cells, as well as primitive human NOD/SCID mouse repopulating cells, can bind extracellular ma

173 ts in a 7-fold increase in correction of NOD/SCID mouse repopulating X-CGD CD34+ PBSCs (14%-22% corre

174 Furthermore, in the presence of NOD/SCID mouse serum, there was no complement-mediated lysis

175 LPS stimulation of SCID mouse splenocytes resulted in measurable IFN-gamma

176 disorder in human cells in vivo with the NOD/SCID mouse system using onco-retrovirus vector.

177 em used the severe combined immunodeficient (scid) mouse that was depleted of NE with 6-hydroxydopami

178 lines in a severe combined immunodeficient (SCID) mouse tibial injection model.

179 human skin-severe combined immunodeficient (SCID) mouse transplant model.

180 one marrow (BM)-derived CD34+ cells in a NOD/SCID mouse transplantation model.

181 CCR5 expression in the SCID mouse was sufficient to clear CCL5, because serum l

182 Transplanted psoriasis plaques on the SCID mouse were treated weekly for 4 weeks with intraper

183 pre-B cell line and in cells from the mutant scid mouse, where they largely conform to the hairpin st

184 iabetic/severe combined immunodeficient (NOD/scid) mouse, which lacks xenoantibodies and therefore al

185 mortal cell line (SPARKY) and transplantable scid mouse xenograft (Sparky-X) from a malignant pleural

186 o therapeutic efficacy was demonstrated in a SCID mouse xenograft leukemia/lymphoma model.

187 In an SCID mouse xenograft model, low-dose metronomic paclitax

188 In SCID mouse xenograft models of anaplastic large cell lym

189 potent in vivo antileukemic activity in NOD/SCID mouse xenograft models of relapsed and chemotherapy

190 used in a severe combined immune deficiency (SCID) mouse xenograft model to characterize a pathway li

191 abetic/severe combined immunodeficiency (NOD/SCID) mouse xenograft model.

192 ctivity in severe combined immunodeficiency (SCID) mouse xenograft models of Hodgkin disease.

193 de rat and severe combined immunodeficiency (SCID) mouse xenograft models of human uveal melanoma, wi

194 the in vivo efficacy of i.p. CPE therapy in SCID mouse xenografts in a highly relevant clinical mode

195 xpressed in severe combined immunodeficient (SCID) mouse xenografts by various human cancer cell line

196 leukemia initiation in anti-CD122-primed NOD/SCID mouse xenotransplantation.

197 abetic/severe combined immune-deficient (NOD/SCID) mouse xenotransplantation assay is the most common